Article

IVI Research Brief Explores Implications of "Value of Hope"

A research brief from the Innovation and Value Initiative (IVI) took a look at how accounting for patients’ attitudes towards risks in treatment outcomes affects value.

A research brief from the Innovation and Value Initiative (IVI) took a look at how accounting for patients’ attitudes towards risks in treatment outcomes affects value. Focusing on non-small cell lung cancer (NSCLC), the brief used the IVI-NSCLC model, an open-source simulation model that assesses the costs, benefits, and risks of sequences of treatment for EGFR-mutated disease. The model also includes an experimental module for calculating the value of hope, which has been suggested as one of the elements to augment conventional cost-effectiveness analysis.

Costs and outcomes for 2 possible treatment sequences were determined and the value of hope was added to the quality-adjusted life years (QALYs) by estimating the QALYs a patient would need to obtain to be indifferent toward the 2 sequences of treatment.

Read the full research brief.

Related Videos
Nini Wu, MD, Navista
Fred Locke, MD, Moffitt Cancer Center and Research Institute
Dr Margrit Wiesendanger
Tom Belmon, CAP, GPBCH
Tom Belmont
Natalie Bedford sitting for a video interview
AJMC background with headshots for Joe DePinto, MBA; Kathi Henson, MBA; and Natalie Bedford | Background image credit: ipopba - stock.adobe.com
Lalan Wilfong, MD
Dr Kimlin Tam Ashing
Nini Wu, MD, MBA
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo